Next Generation Sequencing (NGS)
Next Generation Sequencing describes a variety of high-throughput sequencing methods which highly increase the possible sequencing throughput and decrease the cost per sequenced base pair. In combination, this allows us to sequence not only single fragments or genes, as has been done by Sanger sequencing for many years, but also large panels, whole human exomes or even human genomes in a fast and affordable manner.
CENTOGENE´s next generation sequencing department is mainly based on the Illumina sequencing technology, the current leading technology on the market. It is based on sequencing-by-synthesis (SBS), meaning that sequencing is achieved via synthesis of a new complementary DNA strand.
Downloads for next generation sequencing
Request form - Whole genetic test portfolioDownload
How it works
There are several different approaches which all finally generate millions of small fragments of DNA which are tagged with further special sequences “patient bar codes” and adapters (so-called library) to enable them to bind on a sequencing chip (flow cell).
These chip-bound molecules are amplified (so-called bridge amplification) to generate clusters of identical copies in order to provide a sufficient signal (= clustering).
During the sequencing itself, nucleotides labeled with four different fluorescent dyes flow through the chip and are incorporated into a new DNA strand complementary to the original one. A terminator on each nucleotide ensures that only one nucleotide is incorporated. The sequencer optics (laser/camera) scan the chip to generate an image. Each cluster gives a signal depending on the incorporated nucleotide. By unblocking the last incorporated nucleotide and flowing of further nucleotides, the next cycle is initiated. In this manner, sequences (= reads) with up to 150 bp (from both directions of the DNA molecule) can be generated.
A bioinformatics pipeline is used to assemble the fragments by mapping the reads to the human reference sequence. Each base is sequenced several times thus providing highly accurate variant detection.
Taken together, this technology offers not only high accuracy, but also reliable performance in homopolymeric regions, which contributes to the high quality of CENTOGENE´s genetic diagnostics.
Latest scientific articles
Looking for a one-stop-solution for your laboratory? Join this webinar to learn more about our CentoCloud® for diagnostic NGS panels, clinical bioinformatics & medical interpretation in the oncogenetic workflow.
The objective of this study is to define the clinical phenotype and natural history of sporadic adult-onset degenerative ataxia and to identify putative disease-causing mutations. The primary measure of disease severity was the Scale for the Assessment and Rating of Ataxia (SARA). DNA samples were screened for mutations using a high-coverage ataxia-specific gene panel in combination with next-generation sequencing. The analysis was performed on 249 participants. Our study provides quantitative data on the clinical phenotype and progression of sporadic ataxia with adult onset.
Tired of spending significant money and time only to end up with negative results? Join this webinar to discover a complete and unique test with increased diagnostic accuracy and significant time and cost savings.